Full-Time

Sr Manager/Associate Director

Facilities & Maintenance

Confirmed live in the last 24 hours

Beam Therapeutics

Beam Therapeutics

501-1,000 employees

Develops precision genetic medicines using base editing

No salary listed

Expert

Durham, NC, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • BS degree in a technical discipline (Engineering preferred)
  • 10+ years’ experience leading maintenance personnel within a biotechnology / pharmaceutical / medical device manufacturing environment
  • In depth knowledge and understanding of equipment including utility systems, production equipment and lab equipment
  • Excellent verbal and written communication skills
  • Dynamic interpersonal skills, including the demonstrated ability to manage through influence
  • Background in cGMP manufacturing / operations knowledge
  • Experience developing and managing department budget
  • Experience leading and managing a team
  • Ability to work on multiple projects and manage various priorities and timelines and to adapt quickly to changing circumstances
  • High degree of customer focus (internal/external) and demonstrated collaboration in a team environment
  • Results oriented with the ability to demonstrate resiliency, ownership and drive
Responsibilities
  • Responsible for the facilities and maintenance team activities
  • Coordinate and schedule work based on priorities and ensure all documentation is compliant with GxP practices
  • Responsible for all site facilities, engineering, and maintenance contract agreements and relationships
  • Develop and maintain Standard Operating Procedures for the facilities and CMMS system
  • Responsible for routine shutdown coordination and planning
  • Work as a liaison between Engineering, Maintenance, Production and other Site Business Partners
  • Responsible for maintenance schedule based on work order due dates, equipment and technician availability, planning progress and vendor availability, where necessary
  • Manage facilities vendors, including janitorial and HVAC, electrical, and plumbing contractors
  • Work with third-party vendors for repairs, maintenance, and service contracts, ensuring timely and cost-effective solutions
  • Collaborate with the property manager/landlord on matters related to the building lease and services as required
  • Ensure compliant operations in accordance with site registrations, cGMP, environmental regulations and federal / state requirements
  • Support CAPA, Change Control, Deviation, Risk Analysis, Root Cause Analysis, and other Quality Systems
  • Direct support of FDA/EMA and internal audits
  • Manage a team of maintenance and facilities personnel to schedule work orders based on priorities and ensure all documentation is compliant with GxP practices
  • Business Owner for site CMMS system for both NC and MA
  • Manage, develop and maintain all space planning requirements, including internal employee moves, new hires and floor plans
  • Manage the facilities budget, ensuring cost-effective spending on repairs, maintenance, and capital improvements. Monitor and control expenses to stay within budget guidelines
  • Collect, analyze and report statistical data from CMMS and elsewhere as may be required to provide accurate and current assessment of facility management objectives
  • Develops and drives the risk management programs for the site
  • Continue to develop and maintain the spare parts inventory program
  • Evaluate, specify and recommend new equipment for the site
  • Ensure timely execution of the preventative maintenance and calibration programs.
  • Maintain and refine the standard operating procedures and work instructions for the department
  • Ensure that the organizational structure, technical capability, resources and processes exist to achieve the current and future objectives of the operation
  • Cultivate Beam’s culture and values-driven organization focused on its people
  • Proactively analyze production and facility issues and coordinate potential resolutions with the team
  • Provide technical and personal development mentoring for maintenance personnel
  • Must be willing to have a flexible schedule during process start up and manufacturing runs, which may include supporting critical operations outside of normal work hours, as needed

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise changes to the genetic code to correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures instead of temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and potential commercialization of their treatments after regulatory approval. Beam Therapeutics distinguishes itself from competitors by emphasizing a values-driven approach, a talented team of experts, and a commitment to rigorous scientific development. Their ultimate goal is to advance genetic medicine to improve the lives of patients suffering from genetic disorders.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Beam raised $500 million to advance its R&D and expand its genetic medicine pipeline.
  • Successful Phase 1/2 trial for BEAM-302 shows potential beyond sickle cell disease.
  • Partnership with Eli Lilly highlights commercial potential and industry confidence in Beam's technology.

What critics are saying

  • Increased competition from CRISPR Therapeutics could impact Beam's market share.
  • New CFO appointment may lead to transitional challenges or shifts in financial strategy.
  • $500 million equity offering may dilute existing shareholders' value, causing dissatisfaction.

What makes Beam Therapeutics unique

  • Beam Therapeutics uses base editing, a safer alternative to traditional CRISPR methods.
  • The company focuses on lifelong cures for genetic disorders, not just symptom management.
  • Beam's technology targets single base changes without causing double-stranded DNA breaks.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-1%
Benzinga
Mar 10th, 2025
Beam Therapeutics Reports Data, Raises $500M

Beam Therapeutics announced promising initial safety and efficacy data from its Phase 1/2 trial of BEAM-302 for treating alpha-1 antitrypsin deficiency (AATD). The trial showed BEAM-302 was well tolerated and led to dose-dependent correction of the disease-causing mutation. Beam plans to continue the trial and report further data in 2025. Additionally, Beam raised $500 million through an equity offering. BEAM stock was down 3.44% at $27.50 in premarket trading.

GlobeNewswire
Mar 10th, 2025
Beam Therapeutics Announces Pricing of Underwritten Offering

CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...

GlobeNewswire
Dec 6th, 2024
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024.

CityBiz
Jul 15th, 2024
Beam Therapeutics Chief Financial Officer Terry-Ann Burrell to Retire

CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase.

Securities.io
May 21st, 2024
10 Rare Diseases Specialist Stocks

Rare Diseases – Curing The IncurableWhile not entirely solved, a lot of major deadly illnesses that have plagued humanity have become more manageable over the last century, from bacterial (antibiotics) and viral (vaccines) infections to diabetes (insulin).There is, however, a wide array of rare diseases which are still mostly incurable. Most of the time, this is because these diseases are not caused by an external threat, but by a biological dysfunction inside the very cells of the patient. This is quickly changing, thanks to progress in biosciences.On one hand, with the human genome sequenced and much more advanced analytical methods, scientists can finally understand what are the root causes of rare diseases. Even AI is now helping interpret the data and provide new insights .On the other hand, new technologies like gene editing open the possibility of fixing deficient cells or organs, restoring normal function.Rare diseases each affect less than 1 in 2,000 people, with more than 6000 different rare diseases. Despite their individual rarity, together, they affect around 4% of the population, with as many as 30 million people in just Europe .3/4 of rare diseases affect children, 72% are genetic in origin, and it takes on average 5 years for rare disease patients to get a diagnosis.CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a recently discovered tool for genetic editing. It allows for very precise and directed gene editing, and its discoverers have won the 2020 Nobel Prize .What sets CRISPR Therapeutics apart is the all-star team of founders, including Dr